What are the dosing, monitoring, adverse effects, and dose‑adjustment recommendations for lenvatinib in cancer patients?

Lenvatinib in Cancer Patients: Dosing, Monitoring, Adverse Effects, and Management

Dosing Recommendations

Lenvatinib dosing is weight-based for hepatocellular carcinoma (HCC) and indication-specific for other cancers, with 12 mg daily for patients ≥60 kg and 8 mg daily for patients <60 kg in HCC. 1

Standard Dosing by Indication:

• HCC: 12 mg once daily (body weight ≥60 kg) or 8 mg once daily (body weight <60 kg) 1
• Differentiated Thyroid Cancer (DTC): 24 mg once daily 2
• Renal Cell Carcinoma (RCC): 18 mg once daily (in combination with pembrolizumab) or 20 mg once daily (in combination with everolimus) 2
• Endometrial Carcinoma: 20 mg once daily (in combination with pembrolizumab) 2

Dose Modifications for Organ Dysfunction:

• Severe renal impairment (CrCl 15-29 mL/min): Reduce dose for DTC, RCC, and endometrial carcinoma; no recommended dose for HCC 2
• Severe hepatic impairment (Child-Pugh C): Reduce dose for DTC, RCC, and endometrial carcinoma; no recommended dose for HCC 2
• Mild-moderate hepatic impairment (Child-Pugh A-B): No dose adjustment needed 2

Patient Selection and Eligibility

Lenvatinib is indicated for first-line treatment of advanced HCC in patients with Child-Pugh A liver function, ECOG performance status 0-1, and specific tumor characteristics. 1

Key Inclusion Criteria for HCC:

• Child-Pugh class A liver function 1
• ECOG performance status 0 or 1 1
• Tumor occupying <50% of liver volume 1
• No main portal vein invasion or bile duct invasion 1

Caution in Special Populations:

• Child-Pugh B patients: Real-world data show increased liver-related adverse events and shorter OS, particularly in B8/9 patients 1
• Patients beyond REFLECT criteria: May have lower objective response rates and shorter OS 1
• Patients ≥75 years showed reduced tolerability in HCC 2

Monitoring Requirements

Initiate comprehensive monitoring before and during lenvatinib therapy, with particular attention to blood pressure, proteinuria, and thyroid function. 1

Baseline Assessment:

• Blood pressure measurement 1
• Urinalysis for proteinuria 1
• Thyroid stimulating hormone (TSH) levels 1
• Upper endoscopy within 6 months (when used with bevacizumab) 1
• Liver function tests 1

Ongoing Monitoring:

• Blood pressure: Monitor regularly; hypertension occurs in 42% of patients (grade 3+ in 23%) 1
• Proteinuria:
  • Interrupt lenvatinib if 24-hour urinary protein ≥2 g 1
  • If dipstick shows 2+ or more, use random urinary protein-to-creatinine ratio before 24-hour collection 1
• Thyroid function:
  • Monitor TSH levels regularly 1
  • Consider endocrinology consultation if TSH >10 mIU/L or >5 mIU/L on two separate occasions 1
  • Hypothyroidism occurs in 16% of patients 1

Adverse Effects Profile

Grade ≥3 treatment-related adverse events occur in 57% of lenvatinib-treated patients, significantly higher than sorafenib (49%), with hypertension being the most common serious adverse event. 1

Most Common Adverse Events (Any Grade):

• Hypertension: 42% (grade 3-4: 23%) 1
• Diarrhea: 39% (grade 3-4: 4%) 1
• Anorexia/decreased appetite: 34% (grade 3-4: 5%) 1
• Weight loss: 31% (grade 3-4: 8%) 1
• Fatigue: 30% 1
• Hand-foot skin reaction (HFSR): 27% (grade 3-4: 3%) - notably less than sorafenib (54%) 1
• Proteinuria: 25% 1
• Hypothyroidism: 16% 1

Serious Adverse Events:

• Occur in 43% of patients (vs. 30% with sorafenib) 1
• Treatment discontinuation due to adverse events: 10.7% 1
• Decreased platelet count (grade 3-4): 6% 1
• Elevated AST (grade 3-4): 5% 1

Dose Adjustment Strategy

For persistent or intolerable grade 2 or grade 3 adverse events, interrupt lenvatinib until symptoms improve to grade 0-1 or baseline, then resume at the same or reduced dose. 3

General Principles:

• Grade 1-2 AEs: Generally continue treatment without interruption 3
• Persistent/intolerable grade 2 or grade 3 AEs: Interrupt until improvement to grade 0-1, then resume at same or lower dose 3
• Maintain highest tolerable dose: Relative dose intensity ≤70% associated with significantly shorter PFS 1
• Median treatment duration: 5.7 months 1

Importance of Dose Intensity:

• Patients with objective response had significantly higher relative dose intensity 1
• Shorter dose interruptions correlate with better treatment outcomes 4
• OS significantly shorter in patients who discontinued due to serious adverse events 1
• Hypertension and HFSR are predictors of better prognosis 1

Specific Adverse Event Management

Hypertension (42% incidence):

• Most common grade 3-4 adverse event (23%) 1
• Initiate or optimize antihypertensive therapy 3
• Monitor blood pressure regularly 1

Proteinuria (25% incidence):

• Interrupt treatment if 24-hour urinary protein ≥2 g 1
• Use dipstick screening; if 2+, obtain protein-to-creatinine ratio 1
• Resume at reduced dose once proteinuria improves 3

Hypothyroidism (16% incidence):

• Monitor TSH levels regularly 1
• Initiate levothyroxine therapy when indicated 5
• Median levothyroxine dose: 25-50 μg/day 5
• Median time to onset: 81 days 5
• Risk factors: age ≤63 years, higher daily lenvatinib dose (≥0.152 mg/kg/day) 5

Diarrhea (39% incidence):

• Provide antidiarrheal medications 3
• Ensure adequate hydration 3
• Consider dose interruption for persistent grade 2 or grade 3 3

Hand-Foot Skin Reaction (27% incidence):

• Less frequent than sorafenib (54%) 1
• Apply urea-containing creams 3
• Recommend comfortable footwear with cushioning 3
• Avoid hot water bathing 3
• Provide analgesics as needed 3

Clinical Efficacy Outcomes

Lenvatinib demonstrated non-inferior overall survival to sorafenib (13.6 vs 12.3 months; HR 0.92) with significantly superior progression-free survival (7.4 vs 3.7 months) and objective response rate (24.1% vs 9.2%). 1

Key Efficacy Data:

• Median OS: 13.6 months (95% CI 12.1-14.9) 1
• Median PFS: 7.4 months (HR 0.66; 95% CI 0.57-0.77; p<0.00001) 1
• Median time to progression: 8.9 months 1
• Objective response rate (mRECIST): 24.1% 1
• Objective response rate (RECIST 1.1): 18.8% 1

Prognostic Factors:

• Development of hypertension or HFSR predicts better prognosis 1
• Smaller tumor burden inversely correlated with median duration of response 4
• High tumor burden associated with significantly worse prognosis 4

Critical Pitfalls and Contraindications

Exclude patients with main portal vein invasion, bile duct invasion, or tumor occupying >50% of liver volume, as these were exclusion criteria in the pivotal REFLECT trial. 1

Absolute Contraindications:

• Main portal vein invasion 1
• Clear bile duct invasion 1
• Tumor occupying >50% of total liver volume 1

Relative Contraindications/Cautions:

• Child-Pugh B8/9 liver dysfunction (limited data, increased adverse events) 1
• Clinically symptomatic vascular disease (coronary or peripheral) 1
• Tumor infiltration into trachea or other organs (risk of fistula/perforation) 4
• Age ≥75 years (reduced tolerability in HCC) 2

Special Warnings:

• Risk of upper gastrointestinal bleeding when combined with bevacizumab (requires endoscopy screening) 1
• Not dialyzable due to high plasma protein binding (97-99%) 2
• Hypothyroidism and pneumothorax occur at higher rates in pediatric patients 2